Comparative Evaluation of Sustained Acoustic Medicine Device on Circulation

NCT ID: NCT06510062

Last Updated: 2025-03-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

67 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-22

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Comparative Evaluation of Sustained Acoustic Medicine Device on Circulation

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Measurement of Circulation on Anatomical Locations of the Body

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SAM Ultrasound Device and Diclofenac Patch 1

Patients receive treatment from the SAM Ultrasonic Diathermy Device 1 hour with 2.5% diclofenac ultrasound gel patch on right forearm. The SAM device emits continuous ultrasound at 3-megahertz (MHz) frequency and 0.132 watts/cm2 intensity.

Group Type EXPERIMENTAL

Sustained Acoustic Medicine

Intervention Type DEVICE

The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.

2.5% Diclofenac Patches

Intervention Type DRUG

Topical pain relief gel worn via SAM patch.

SAM Ultrasound Device and Diclofenac Patch 2

Patients receive treatment from the SAM Ultrasonic Diathermy Device 1 hour with 2.5% diclofenac ultrasound gel patch on left forearm. The SAM device emits continuous ultrasound at 3-megahertz (MHz) frequency and 0.132 watts/cm2 intensity.

Group Type EXPERIMENTAL

Sustained Acoustic Medicine

Intervention Type DEVICE

The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.

2.5% Diclofenac Patches

Intervention Type DRUG

Topical pain relief gel worn via SAM patch.

SAM Ultrasound Device and SAM Patch 1

Patients receive treatment from the SAM Ultrasonic Diathermy Device 1 hour with standard ultrasound gel patch on right forearm. The SAM device emits continuous ultrasound at 3-megahertz (MHz) frequency and 0.132 watts/cm2 intensity.

Group Type EXPERIMENTAL

Sustained Acoustic Medicine

Intervention Type DEVICE

The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.

SAM Ultrasound Device and SAM Patch 2

Patients receive treatment from the SAM Ultrasonic Diathermy Device 1 hour with standard ultrasound gel patch on left forearm. The SAM device emits continuous ultrasound at 3-megahertz (MHz) frequency and 0.132 watts/cm2 intensity.

Group Type EXPERIMENTAL

Sustained Acoustic Medicine

Intervention Type DEVICE

The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sustained Acoustic Medicine

The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.

Intervention Type DEVICE

Sustained Acoustic Medicine

The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.

Intervention Type DEVICE

Sustained Acoustic Medicine

The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.

Intervention Type DEVICE

Sustained Acoustic Medicine

The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.

Intervention Type DEVICE

2.5% Diclofenac Patches

Topical pain relief gel worn via SAM patch.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SAM Wearable Ultrasound Device Long Duration Ultrasound LITUS Device Wearable Long Duration Low-Intensity Device SAM Wearable Ultrasound Device Long Duration Ultrasound LITUS Device Wearable Long Duration Low-Intensity Device SAM Wearable Ultrasound Device Long Duration Ultrasound LITUS Device Wearable Long Duration Low-Intensity Device SAM Wearable Ultrasound Device Long Duration Ultrasound LITUS Device Wearable Long Duration Low-Intensity Device

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy Volunteer

Exclusion Criteria

* Is pregnant/nursing
* Has an active infection, open sores, or wounds in the treatment area
* Has any preexisting extremity circulation condition
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ZetrOZ, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

George K Lewis, PhD

Role: PRINCIPAL_INVESTIGATOR

ZetrOZ Systems LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

ZetrOZ Systems LLC

Trumbull, Connecticut, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Scanzuso A, Hendren T, Egmont M, Zarkar J, Roberge M. Sustained acoustic medicine increases local circulation with a diclofenac delivery patch: a randomized placebo controlled study. Front Med Technol. 2025 Jul 4;7:1552294. doi: 10.3389/fmedt.2025.1552294. eCollection 2025.

Reference Type DERIVED
PMID: 40687068 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CR-01-2024

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Same Day Discharge
NCT02943512 UNKNOWN NA
Ventricular Pace Suppression Study
NCT01053832 COMPLETED NA
ECG Belt for CRT Response
NCT03504020 COMPLETED NA
Arrhythmia Detection After MI
NCT05073419 RECRUITING NA